KR20170002645A - 개선된 면역글로불린 가변 도메인 - Google Patents

개선된 면역글로불린 가변 도메인 Download PDF

Info

Publication number
KR20170002645A
KR20170002645A KR1020167035012A KR20167035012A KR20170002645A KR 20170002645 A KR20170002645 A KR 20170002645A KR 1020167035012 A KR1020167035012 A KR 1020167035012A KR 20167035012 A KR20167035012 A KR 20167035012A KR 20170002645 A KR20170002645 A KR 20170002645A
Authority
KR
South Korea
Prior art keywords
amino acid
domain
acid residue
residue
library
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167035012A
Other languages
English (en)
Korean (ko)
Inventor
마리에-안게 부이세
카를로 보우톤
Original Assignee
아블린쓰 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아블린쓰 엔.브이. filed Critical 아블린쓰 엔.브이.
Priority to KR1020237012548A priority Critical patent/KR102827683B1/ko
Priority to KR1020237012493A priority patent/KR102769509B1/ko
Publication of KR20170002645A publication Critical patent/KR20170002645A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020167035012A 2014-05-16 2015-05-13 개선된 면역글로불린 가변 도메인 Ceased KR20170002645A (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020237012548A KR102827683B1 (ko) 2014-05-16 2015-05-13 개선된 면역글로불린 가변 도메인
KR1020237012493A KR102769509B1 (ko) 2014-05-16 2015-05-13 개선된 면역글로불린 가변 도메인

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201461994552P 2014-05-16 2014-05-16
US61/994,552 2014-05-16
US201462014015P 2014-06-18 2014-06-18
US201461014015P 2014-06-18 2014-06-18
US62/014,015 2014-06-18
US201462040167P 2014-08-21 2014-08-21
US62/040,167 2014-08-21
US201462047560P 2014-09-08 2014-09-08
US62/047,560 2014-09-08
US201562133600P 2015-03-16 2015-03-16
US62/133,600 2015-03-16
PCT/EP2015/060643 WO2015173325A2 (en) 2014-05-16 2015-05-13 Improved immunoglobulin variable domains

Related Child Applications (3)

Application Number Title Priority Date Filing Date
KR1020237012548A Division KR102827683B1 (ko) 2014-05-16 2015-05-13 개선된 면역글로불린 가변 도메인
KR1020187022490A Division KR20180091115A (ko) 2014-05-16 2015-05-13 개선된 면역글로불린 가변 도메인
KR1020237012493A Division KR102769509B1 (ko) 2014-05-16 2015-05-13 개선된 면역글로불린 가변 도메인

Publications (1)

Publication Number Publication Date
KR20170002645A true KR20170002645A (ko) 2017-01-06

Family

ID=91193230

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020237033317A Pending KR20230145503A (ko) 2014-05-16 2015-05-13 개선된 면역글로불린 가변 도메인
KR1020167035012A Ceased KR20170002645A (ko) 2014-05-16 2015-05-13 개선된 면역글로불린 가변 도메인
KR1020187022490A Ceased KR20180091115A (ko) 2014-05-16 2015-05-13 개선된 면역글로불린 가변 도메인
KR1020237012548A Active KR102827683B1 (ko) 2014-05-16 2015-05-13 개선된 면역글로불린 가변 도메인
KR1020237012493A Active KR102769509B1 (ko) 2014-05-16 2015-05-13 개선된 면역글로불린 가변 도메인

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020237033317A Pending KR20230145503A (ko) 2014-05-16 2015-05-13 개선된 면역글로불린 가변 도메인

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020187022490A Ceased KR20180091115A (ko) 2014-05-16 2015-05-13 개선된 면역글로불린 가변 도메인
KR1020237012548A Active KR102827683B1 (ko) 2014-05-16 2015-05-13 개선된 면역글로불린 가변 도메인
KR1020237012493A Active KR102769509B1 (ko) 2014-05-16 2015-05-13 개선된 면역글로불린 가변 도메인

Country Status (24)

Country Link
US (10) US12180268B2 (enExample)
EP (4) EP3248986B1 (enExample)
JP (6) JP7325928B2 (enExample)
KR (5) KR20230145503A (enExample)
CN (3) CN106661100A (enExample)
AU (6) AU2015261536B2 (enExample)
BR (2) BR112016026773A2 (enExample)
CA (2) CA2948076A1 (enExample)
DK (2) DK3248986T3 (enExample)
ES (2) ES2815572T3 (enExample)
HR (2) HRP20220400T1 (enExample)
HU (2) HUE058008T2 (enExample)
IL (6) IL299282B2 (enExample)
LT (2) LT3248986T (enExample)
MX (4) MX383560B (enExample)
PH (1) PH12016502282B1 (enExample)
PL (2) PL3143042T3 (enExample)
PT (2) PT3143042T (enExample)
RS (2) RS60717B1 (enExample)
RU (1) RU2746738C2 (enExample)
SG (3) SG10201805288QA (enExample)
SI (2) SI3248986T1 (enExample)
WO (1) WO2015173325A2 (enExample)
ZA (5) ZA201607587B (enExample)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CA2837998C (en) * 2011-06-23 2022-03-01 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
KR20230145503A (ko) * 2014-05-16 2023-10-17 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
KR20250099289A (ko) 2014-05-16 2025-07-01 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
WO2016118733A1 (en) 2015-01-21 2016-07-28 Inhibrx Biopharma LLC Non-immunogenic single domain antibodies
NO2768984T3 (enExample) * 2015-11-12 2018-06-09
HK1258507A1 (zh) * 2015-11-12 2019-11-15 Ablynx Nv 改进的p2x7受体结合剂和包含其的多肽
SI3374392T1 (sl) * 2015-11-13 2022-04-29 Ablynx Nv Izboljšane variabilne domene imunoglobulina, ki vežejo serumski albumin
CA3004748C (en) 2015-11-18 2021-11-16 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
MX2018006246A (es) * 2015-11-18 2018-08-01 Merck Sharp & Dohme Aglutinantes ctla4p.
AU2016357460B2 (en) 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
US10544222B2 (en) 2015-11-18 2020-01-28 Merck Sharp & Dohme Corp. PD1/CTLA4 binders
CA3014443A1 (en) 2016-02-12 2017-08-17 Ablynx Nv Method for the production of immunoglobulin single variable domains
CN107400166A (zh) * 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 针对ctla4的单域抗体及其衍生蛋白
CN109313183B (zh) 2016-06-23 2022-10-21 埃博灵克斯股份有限公司 免疫球蛋白单可变结构域的改进的药代动力学测定
BR112019010061A2 (pt) 2016-11-16 2019-08-13 Ablynx Nv polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta
KR20230061582A (ko) * 2016-12-07 2023-05-08 아블린쓰 엔.브이. 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인
LT3571225T (lt) 2017-01-17 2024-11-11 Ablynx Nv Patobulintos serumo albumino rišamosios medžiagos
RS66173B1 (sr) 2017-01-17 2024-12-31 Ablynx NV Poboljšana veziva serumskog albumina
KR20250011229A (ko) 2017-06-02 2025-01-21 메르크 파텐트 게엠베하 Adamts 결합성 면역글로불린
CN111108126B (zh) 2017-07-19 2024-04-26 非营利性组织佛兰芒综合大学生物技术研究所 血清白蛋白结合剂
EP4635987A3 (en) 2017-10-31 2026-01-14 Vib Vzw Novel antigen-binding chimeric proteins and methods and uses thereof
US12465640B2 (en) 2019-02-25 2025-11-11 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ECM-affinity peptides linked to anti-inflammatory agents
WO2020221888A1 (en) 2019-04-30 2020-11-05 Vib Vzw Cystic fibrosis transmembrane conductance regulator stabilizing agents
EP4065603A1 (en) 2019-11-27 2022-10-05 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
JP7719775B2 (ja) 2019-12-06 2025-08-06 アブリンクス エン．ヴェー． ＴＮＦαおよびＯＸ４０Ｌを標的とする免疫グロブリン単一可変ドメインを含むポリペプチド
CN114981300B (zh) 2019-12-06 2025-10-31 艾伯霖克斯公司 包含靶向TNFα和IL-23的免疫球蛋白单个可变结构域的多肽
JP7641968B2 (ja) 2019-12-09 2025-03-07 アブリンクス エン．ヴェー． Ｉｌ－１３およびｔｓｌｐを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
US20240027467A1 (en) 2019-12-20 2024-01-25 Vib Vzw Nanobody Exchange Chromatography
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
CN115698047A (zh) 2020-02-25 2023-02-03 非营利性组织佛兰芒综合大学生物技术研究所 富含亮氨酸的重复激酶2变构调节剂
IL296767A (en) 2020-03-30 2022-11-01 Ablynx Nv Method for the production and purification of multivalent immunoglobulin single variable domains
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
EP4192877A4 (en) * 2020-08-05 2024-10-16 Synthekine, Inc. SYNTHETIC IL2RB/IL2RG CYTOKINES
WO2022063984A1 (en) 2020-09-25 2022-03-31 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
EP4263602A1 (en) * 2020-12-18 2023-10-25 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha
CA3205422A1 (en) 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
US20240092919A1 (en) 2020-12-18 2024-03-21 Ablynx N. V. T cell recruiting polypeptides based on tcr alpha/beta reactivity
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
CA3207548A1 (en) 2021-02-05 2022-08-11 Xavier Saelens Sarbecovirus binders
IL305318A (en) 2021-02-19 2023-10-01 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
WO2022206900A1 (zh) * 2021-04-01 2022-10-06 江苏先声药业有限公司 抗人血清白蛋白(hsa)的纳米抗体及其应用
CA3228014A1 (en) 2021-07-30 2023-02-16 Vib Vzm Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
CN118339179A (zh) * 2021-11-29 2024-07-12 江苏恒瑞医药股份有限公司 经修饰的蛋白或多肽
AU2022409733A1 (en) 2021-12-17 2024-08-01 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123
US20250304664A1 (en) 2022-01-12 2025-10-02 Vib Vzw Human NTCP Binders For Therapeutic Use And Liver-Specific Targeted Delivery
US20250235534A1 (en) 2022-04-13 2025-07-24 Vib Vzw An LTBR Agonist In Combination Therapy Against Cancer
EP4273162A1 (en) * 2022-05-06 2023-11-08 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
AU2023265474A1 (en) 2022-05-06 2024-10-31 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
EP4526340A1 (en) 2022-05-18 2025-03-26 Vib Vzw Sarbecovirus spike s2 subunit binders
TW202423482A (zh) 2022-06-08 2024-06-16 美商泰德治療公司 可電離陽離子脂質和脂質奈米顆粒、及其合成方法和用途
IL317588A (en) 2022-06-14 2025-02-01 Ablynx Nv Single immunoglobulin variable sites targeting the T cell receptor
CN120077065A (zh) 2022-07-27 2025-05-30 阿布林克斯有限公司 与新生儿Fc受体的特定表位结合的多肽
EP4594348A1 (en) 2022-09-27 2025-08-06 Vib Vzw Antivirals against human parainfluenza virus
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
CN120380024A (zh) 2022-12-21 2025-07-25 建新公司 抗pd-1×4-1bb结合蛋白
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
WO2024151515A2 (en) 2023-01-09 2024-07-18 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
KR20250133776A (ko) 2023-02-10 2025-09-08 아뮤닉스 파마슈티컬스, 인크. 전립선-특이적 막 항원(psma)을 표적화하는 조성물 및 이의 제조 방법 및 사용 방법
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors
CN121263437A (zh) 2023-03-14 2026-01-02 奥德赛治疗股份有限公司 抗cd25抗原结合蛋白及其用途
WO2024208816A1 (en) 2023-04-03 2024-10-10 Vib Vzw Blood-brain barrier crossing antibodies
WO2024231447A1 (en) 2023-05-08 2024-11-14 Sanofi Glycosylation of immunoglobulin single variable domains
TW202448951A (zh) 2023-05-17 2024-12-16 美商奧迪希治療公司 經修飾之單域抗體
WO2024261235A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Chimeric proteins for modulating cytokine receptor activity
WO2025006846A2 (en) 2023-06-29 2025-01-02 Odyssey Therapeutics, Inc. Anti-trailr2 antigen-binding proteins and uses thereof
AR133188A1 (es) 2023-07-05 2025-09-03 Ablynx Nv ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
AR133725A1 (es) 2023-09-04 2025-10-29 Sanofi Sa Polipéptidos para uso en el tratamiento de tumores que expresan glipicano-3
AR133903A1 (es) 2023-09-22 2025-11-12 Ablynx Nv Agentes de unión de albúmina bi- y multivalentes
WO2025080751A2 (en) 2023-10-13 2025-04-17 Odyssey Therapeutics, Inc. Anti-cdh17 antigen-binding proteins and uses thereof
WO2025099632A1 (en) 2023-11-08 2025-05-15 Sanofi Cd25 based lysosomal degrader and uses thereof
WO2025109176A1 (en) 2023-11-22 2025-05-30 Exevir Bio Bv Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
TW202540188A (zh) 2023-12-01 2025-10-16 比利時商艾伯霖克斯公司 精準活化的多肽
WO2025125577A1 (en) 2023-12-14 2025-06-19 Vib Vzw Antibodies against influenza b virus
US20250236673A1 (en) 2023-12-22 2025-07-24 Ablynx N.V. Protein-based carriers for site-specific amine conjugation
WO2025133253A2 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery
WO2025174825A2 (en) 2024-02-12 2025-08-21 Aera Therapeutics, Inc. Delivery compositions
WO2025181155A1 (en) 2024-02-26 2025-09-04 Vib Vzw Human beta-glucocerebrosidase binders and uses thereof
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
US12459994B2 (en) 2024-04-12 2025-11-04 Paragon Therapeutics, Inc. Albumin binding proteins and methods of use
WO2025219231A1 (en) 2024-04-15 2025-10-23 Vib Vzw Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
WO2025255558A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
WO2025255435A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Antigen-binding proteins against serum albumin and uses thereof
WO2025262150A2 (en) 2024-06-18 2025-12-26 Ablynx Nv Antibody-recruiting molecules
WO2026006708A2 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
WO2026006809A1 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Multispecific molecules binding tnfr2 and cd25 and uses thereof
WO2026008664A1 (en) 2024-07-01 2026-01-08 Vib Vzw Allosteric modulators of inhibitory immune receptor complexes

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545106C3 (de) * 1963-07-16 1979-05-31 Union Carbide Corp., New York, N.Y. (V.St.A.) Verfahren zur Herstellung von linearen Polyarylenpolyäthern
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5248775A (en) 1989-12-11 1993-09-28 The Trustees Of Princeton University Pyrrolo(2,3-d)pyrimidines
KR0162654B1 (ko) 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US4996206A (en) 1989-12-11 1991-02-26 The Trustees Of Princeton University N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
ATE203767T1 (de) 1992-08-21 2001-08-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
EP1469883A2 (en) 1998-02-19 2004-10-27 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
EP2364997A3 (en) 1999-01-15 2012-07-04 Genentech, Inc. Polypeptide variants with altered effector function
WO2002057445A1 (en) * 2000-05-26 2002-07-25 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
WO2004003019A2 (en) 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs
WO2003035695A2 (en) 2001-07-26 2003-05-01 Tanox, Inc. Agents that activate or inhibit toll-like receptor 9
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
BRPI0316092B8 (pt) 2002-11-08 2021-05-25 Ablynx Nv anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
RU2357974C2 (ru) 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
AU2005227326B2 (en) 2004-03-24 2009-12-03 Xencor, Inc. Immunoglobulin variants outside the Fc region
CA2569240A1 (en) 2004-06-01 2005-12-15 Domantis Limited Drug fusion comprising a polypeptide drug and an immunoglobulin heavy chain variable domain specific for serum albumin
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
WO2006059106A2 (en) 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
JP2008521870A (ja) 2004-12-02 2008-06-26 ドマンティス リミテッド 抗ｉｌ−１ｒ１単一ドメイン抗体および治療使用
EP3613767A1 (en) 2005-05-18 2020-02-26 Ablynx N.V. Improved nanobodiestm against tumor cecrosis factor-alpha
EP3415535B1 (en) 2005-05-20 2020-12-09 Ablynx N.V. Improved nanobodies tm for the treatment of aggregation-mediated disorders
WO2006129843A2 (en) 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Bispecific capturing molecule
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
JP2009519011A (ja) 2005-12-01 2009-05-14 ドマンティス リミテッド インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
US20080311111A1 (en) 2005-12-01 2008-12-18 Drew Philip D Competitive Domain Antibody Formats That Bind Interleukin 1 Receptor Type 1
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
EP1976991A1 (en) 2006-01-24 2008-10-08 Domantis Limited Fusion proteins that contain natural junctions
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
US20080267949A1 (en) 2006-12-05 2008-10-30 Ablynx N.V. Peptides capable of binding to serum proteins
AU2007331672A1 (en) 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
CA2687903C (en) 2007-05-24 2016-09-13 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
PL2158315T3 (pl) * 2007-06-25 2016-10-31 Sposoby modyfikowania przeciwciał i zmodyfikowane przeciwciała o ulepszonych właściwościach funkcjonalnych
CA2706425A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
JP2011517561A (ja) 2008-03-31 2011-06-16 グラクソ グループ リミテッド 薬物融合体および複合体
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
WO2009138494A2 (en) * 2008-05-15 2009-11-19 Ablynx N.V. Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
AU2009248049B2 (en) 2008-05-16 2015-07-23 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
EP2143735A1 (en) * 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010042815A2 (en) 2008-10-09 2010-04-15 Duke University Vhh antibody fragments for use in the detection and treatment of cancer
CN104127880A (zh) 2009-03-27 2014-11-05 葛兰素集团有限公司 药用融合体和缀合物
PT2424889E (pt) 2009-04-30 2015-11-12 Ablynx Nv Método de produção de anticorpos de domínio
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
WO2010142534A1 (en) 2009-05-27 2010-12-16 Ablynx Nv Biparatopic protein constructs directed against il-23
KR20140014405A (ko) 2009-05-28 2014-02-06 글락소 그룹 리미티드 안구 질병을 치료하거나 예방하는데 사용되는 ｔｎｆ-알파 길항제 및 ｖｅｇｆ 길항제의 조합물
US9150640B2 (en) 2009-07-10 2015-10-06 Ablynx N.V. Method for the production of variable domains
US8306355B2 (en) 2009-07-13 2012-11-06 Sharp Laboratories Of America, Inc. Methods and systems for reducing compression artifacts
US20110117113A1 (en) 2009-10-09 2011-05-19 Gerald Beste Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
EP2513145B1 (en) 2009-12-14 2018-01-24 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
MX352871B (es) * 2009-12-23 2017-12-13 Esbatech Alcon Biomed Res Unit Método para disminuir inmunogenicidad.
SG183369A1 (en) 2010-03-03 2012-09-27 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
EP2552962B1 (en) 2010-03-26 2016-03-23 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
CN102971341A (zh) 2010-04-30 2013-03-13 埃博灵克斯股份有限公司 针对异二聚体细胞因子IL-23的p19亚基的纳米抗体的氨基酸序列
BR112012029588A2 (pt) 2010-05-20 2017-07-25 Ablynx Nv materiais biológicas relacionados a her3.
WO2011161266A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Improved immunoglobulin single variable domains and constructs thereof directed against cxcr4
JP2013145769A (ja) 2010-08-04 2013-07-25 Kri Inc 異方性希土類ボンド磁石とその製造方法
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
WO2012104227A1 (en) 2011-02-02 2012-08-09 Glaxo Group Limited Novel antigen binding proteins
JP6181040B2 (ja) 2011-03-28 2017-08-16 アブリンクス エン．ヴェー． 二特異性抗ｃｘｃｒ７免疫グロブリン単一可変ドメイン
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
JP2014525736A (ja) 2011-06-23 2014-10-02 アブリンクス エン．ヴェー． ＩｇＥに対する免疫グロブリン単一可変ドメイン
US9573992B2 (en) 2011-06-23 2017-02-21 Ablynx N.V. Serum albumin binding proteins
CA2837998C (en) * 2011-06-23 2022-03-01 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
US20130019175A1 (en) 2011-07-14 2013-01-17 Microsoft Corporation Submenus for context based menu system
ES2813432T3 (es) * 2011-08-17 2021-03-23 Glaxo Group Ltd Proteínas y péptidos modificados
CN103889451B (zh) 2011-09-30 2016-06-29 埃博灵克斯股份有限公司 与C-Met相关的生物物质
RU2743589C2 (ru) * 2011-10-17 2021-02-20 Регенерон Фармасьютикалс, Инк. Мыши с ограниченной тяжелой цепью иммуноглобулина
US20130129727A1 (en) 2011-11-17 2013-05-23 Nanjingjinsirui Science & Technology Biology Corporation Methods and systems for increasing protein stability
DK3453723T3 (da) * 2012-01-31 2021-09-13 Regeneron Pharma Anti-ASIC1-antistoffer og anvendelser deraf
US9908935B2 (en) 2012-06-01 2018-03-06 Ablynx N.V. P2X7 receptor antagonists and agonists
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
EP2895510A2 (en) 2012-09-13 2015-07-22 Novartis AG Single domain antibody with c-terminal modification
US9667316B2 (en) 2013-05-17 2017-05-30 The Boeing Company Aircraft data transmission using phase separation
KR20230145503A (ko) 2014-05-16 2023-10-17 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
BR112018008754A2 (pt) 2015-10-30 2018-10-30 Ablynx Nv polipeptídeo contra il-23
NO2768984T3 (enExample) 2015-11-12 2018-06-09
HK1258507A1 (zh) 2015-11-12 2019-11-15 Ablynx Nv 改进的p2x7受体结合剂和包含其的多肽
SI3374392T1 (sl) 2015-11-13 2022-04-29 Ablynx Nv Izboljšane variabilne domene imunoglobulina, ki vežejo serumski albumin
CA3004748C (en) 2015-11-18 2021-11-16 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
AU2016357460B2 (en) 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
US10544222B2 (en) 2015-11-18 2020-01-28 Merck Sharp & Dohme Corp. PD1/CTLA4 binders
MX2018006246A (es) 2015-11-18 2018-08-01 Merck Sharp & Dohme Aglutinantes ctla4p.
RS66173B1 (sr) 2017-01-17 2024-12-31 Ablynx NV Poboljšana veziva serumskog albumina
CN114981300B (zh) 2019-12-06 2025-10-31 艾伯霖克斯公司 包含靶向TNFα和IL-23的免疫球蛋白单个可变结构域的多肽
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
EP4263602A1 (en) 2020-12-18 2023-10-25 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha

Also Published As

Publication number Publication date
AU2020202570A1 (en) 2020-05-07
RS60717B1 (sr) 2020-09-30
CA2948076A1 (en) 2015-11-19
JP7098439B2 (ja) 2022-07-11
JP7471987B2 (ja) 2024-04-22
JP2017518072A (ja) 2017-07-06
SG11201609162SA (en) 2016-12-29
AU2020202855A1 (en) 2020-05-21
PL3248986T3 (pl) 2022-05-16
RU2018120744A (ru) 2018-11-15
SI3248986T1 (sl) 2022-04-29
RU2746738C2 (ru) 2021-04-20
EP3248986B1 (en) 2022-01-26
US11220539B2 (en) 2022-01-11
US20210087261A1 (en) 2021-03-25
EP3248986A2 (en) 2017-11-29
BR112016026773A2 (pt) 2017-12-12
CA3175002A1 (en) 2015-11-19
IL248636B (en) 2022-12-01
US20200231662A1 (en) 2020-07-23
US20210269515A1 (en) 2021-09-02
JP2021130681A (ja) 2021-09-09
US11319364B2 (en) 2022-05-03
MX2016014926A (es) 2017-05-09
SI3143042T1 (sl) 2020-08-31
AU2022279374A1 (en) 2023-01-19
ES2815572T3 (es) 2021-03-30
BR122018009619B1 (pt) 2024-01-02
US20210261653A1 (en) 2021-08-26
AU2018204226A1 (en) 2018-07-05
RU2021107470A (ru) 2021-05-17
KR102769509B1 (ko) 2025-02-17
PT3143042T (pt) 2020-09-01
US20220135657A9 (en) 2022-05-05
AU2020202570B2 (en) 2022-12-08
RS63085B1 (sr) 2022-04-29
ZA201607587B (en) 2022-05-25
KR102827683B1 (ko) 2025-06-30
SG10201810124PA (en) 2018-12-28
ES2912069T3 (es) 2022-05-24
IL259972A (en) 2018-07-31
HUE050007T2 (hu) 2020-11-30
CN109053885A (zh) 2018-12-21
IL281755B1 (en) 2023-01-01
IL311293A (en) 2024-05-01
HRP20220400T1 (hr) 2022-05-27
HUE058008T2 (hu) 2022-06-28
CN113717280A (zh) 2021-11-30
JP2024069377A (ja) 2024-05-21
MX383560B (es) 2025-03-14
US20220251183A1 (en) 2022-08-11
US20170121399A1 (en) 2017-05-04
PL3143042T3 (pl) 2020-11-16
JP7454525B2 (ja) 2024-03-22
ZA202004758B (en) 2022-08-31
AU2020202855B2 (en) 2022-12-08
JP7325928B2 (ja) 2023-08-15
IL281755B2 (en) 2023-05-01
US11312765B2 (en) 2022-04-26
JP2021006563A (ja) 2021-01-21
US20220119512A1 (en) 2022-04-21
KR20230054503A (ko) 2023-04-24
IL248636A0 (en) 2017-01-31
US20220332806A1 (en) 2022-10-20
WO2015173325A3 (en) 2016-02-18
IL259972B (en) 2021-04-29
IL295534B1 (en) 2024-11-01
EP3248986A3 (en) 2017-12-20
US11485778B2 (en) 2022-11-01
US11708404B2 (en) 2023-07-25
EP3693386A1 (en) 2020-08-12
JP2024041939A (ja) 2024-03-27
US11312764B2 (en) 2022-04-26
PH12016502282B1 (en) 2024-05-22
PH12016502282A1 (en) 2017-02-13
MX2021007020A (es) 2021-08-05
LT3248986T (lt) 2022-03-25
IL281755A (en) 2021-05-31
NZ726448A (en) 2023-02-24
IL295534B2 (en) 2025-03-01
LT3143042T (lt) 2020-07-27
JP2018162297A (ja) 2018-10-18
DK3143042T3 (da) 2020-08-31
AU2022279374B2 (en) 2026-01-15
EP3143042A2 (en) 2017-03-22
IL299282B1 (en) 2024-05-01
IL299282A (en) 2023-02-01
US12180268B2 (en) 2024-12-31
RU2016149463A (ru) 2018-06-19
SG10201805288QA (en) 2018-07-30
WO2015173325A8 (en) 2016-12-29
IL248636B2 (en) 2023-04-01
ZA202100742B (en) 2022-09-28
IL295534A (en) 2022-10-01
EP3702369A1 (en) 2020-09-02
IL311293B2 (en) 2025-07-01
IL311293B1 (en) 2025-03-01
HRP20200966T1 (hr) 2020-10-16
US11485777B2 (en) 2022-11-01
KR20230053002A (ko) 2023-04-20
CN106661100A (zh) 2017-05-10
MX2023010731A (es) 2023-09-20
MX2018007581A (es) 2020-11-12
EP3143042B1 (en) 2020-06-10
US20210269514A1 (en) 2021-09-02
KR20230145503A (ko) 2023-10-17
ZA202004759B (en) 2022-08-31
RU2016149463A3 (enExample) 2018-07-04
AU2015261536B2 (en) 2020-05-07
AU2022279373A1 (en) 2023-01-19
US20220332807A1 (en) 2022-10-20
WO2015173325A2 (en) 2015-11-19
PT3248986T (pt) 2022-04-05
IL299282B2 (en) 2024-09-01
RU2018120744A3 (enExample) 2022-01-28
KR20180091115A (ko) 2018-08-14
DK3248986T3 (da) 2022-04-04
ZA202004757B (en) 2022-08-31
AU2015261536A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
JP7454525B2 (ja) 改善された免疫グロブリン可変ドメイン
USRE50682E1 (en) Immunoglobulin variable domains
RU2809788C2 (ru) Улучшенные вариабельные домены иммуноглобулина
RU2845084C2 (ru) Улучшенные вариабельные домены иммуноглобулина
HK40035363A (en) Immunoglobulin variable domains
HK40033677A (en) Immunoglobulin variable domains

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

J301 Trial decision

Free format text: TRIAL NUMBER: 2023101000810; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20230412

Effective date: 20230822

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20230822

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2016 7035012

Appeal request date: 20230412

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2023101000810

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301